@article{TGH3541,
author = {Wei Zhang},
title = {Sorafenib in adjuvant setting: call for precise and personalized therapy},
journal = {Translational Gastroenterology and Hepatology},
volume = {1},
number = {1},
year = {2016},
keywords = {},
abstract = {We read with great interest of the negative result of STORM (1). In the study, 1,114 patients were randomly assigned to sorafenib group and placebo group. After a median duration of treatment of 12.5 months, no difference in median recurrence-free survival (RFS) between the two groups was shown [33.3 months in the sorafenib group vs. 33.7 months in the placebo group; hazard ratio (HR) 0.940; 95% CI: 0.780–1.134; one-sided P=0.26].},
issn = {2415-1289}, url = {https://tgh.amegroups.org/article/view/3541}
}